Cell Therapy Market Analysis

Therapy Type (Allogeneic, Autologous)

Autologous segment is estimated to hold more than 92% cell therapy market share by 2037. The segment growth can be attributed to the rising burden of genetic disorders. It was reported in 2022 that every year, more than 200,000 newborns worldwide are born with sickle cell disease, accounting for about 4% of the global population.

Patient-specific autologous cell therapy shows potential in treating a broad range of inherited and acquired human disorders. Autologous cell therapy is a type of customized medicine in which sickness is treated with the patient's own genetically modified immune cells and has shown successful results in treating genetic abnormalities.

Therapeutic Area (Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology)

Throughout the projected period, the oncology segment in cell therapy market is expected to grow at the fastest rate. The growing prevalence of blood cancer is the primary driver of the segment's growth. For instance, more than 1 million instances of blood cancer are reported globally each year, making up roughly 5% of all cancer cases.

The Food and Drug Administration has recognized CAR-T cell therapy as one of the most promising forms of blood cancer treatment through targeting and destroying cancer cells by stimulating the immune system.

Use (Clinical, Research)

For the forecast timeline, the research segment in cell therapy market is likely to register a significant revenue share aided by the rising popularity of stem cell therapy. Stem cell treatment is becoming a very promising and cutting-edge area of scientific study that has created new opportunities for patients with untreated diseases and disorders.

Since stem cell treatments are highly effective and have success rates as high as over 75%, their popularity has grown substantially.

The advancement of stem cell research has significant potential for the creation of innovative treatments for significant and common human illnesses. Stem cells are currently being investigated for their potential to restore brain damage and are being researched for the treatment of osteoarthritis, heart failure, type 1 diabetes, and amyotrophic lateral sclerosis, among other illnesses.

Our in-depth analysis of the market includes the following segments: